Dr. Lal PathLabs Reports Strong Q1 FY26 Results
Mumbai: Dr. Lal PathLabs Limited, a leading diagnostic and related healthcare service provider, has announced its financial results for the quarter ended June 30, 2025. The company reported impressive growth in revenue, EBITDA, and PAT.
Key Highlights
- Revenue Growth: Dr. Lal PathLabs recorded revenue of ₹670 crore in Q1 FY26, an 11.3% increase compared to Q1 FY25.
- EBITDA Growth: EBITDA increased by 13.1% to ₹192.5 crore, with a margin of 28.7%, surpassing expectations.
- PAT Growth: Profit After Tax (PAT) rose 24.3% to ₹132 crore, with a margin of 20.0%.
- Interim Dividend: The board declared an interim dividend of ₹6 per share for FY26, with a record date of August 6, 2025.
Operational Performance
- Sample Volumes: The company reported a 10.7% year-on-year increase in sample volumes, reaching 23.4 million.
- Patient Visits: Patient visits rose 6% to 7.6 million.
- Revenue Contribution: Preventive testing under the ‘Swasthfit’ portfolio contributed 27% of total revenues during the quarter.
Dr. Lal PathLabs’ strong performance and shareholder payout reflect the company’s continued focus on profitable growth and confidence in maintaining momentum in the diagnostics sector.
